-
Mashup Score: 0
Abstract Background The intensity of inflammation during COVID-19 is related to adverse outcomes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in low-density lipoprotein recept…
Categories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 0
Taking proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors was associated with lower rates of death and fewer instances of intubation among patients with severe cases of COVID-19, according to a new study in the Journal of the American College of Cardiology.[1] Increase in COVID-19 survival rates with PCSK9 inhibitors Sometimes used for cholesterol management, PCSK9 inhibitors…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Can #PCSK9 inhibitors decrease vascular inflammation in sever COVID-19 patients, leading to lower mortality rates? A new @JACCJournals pilot study explores. https://t.co/q7paQsZi03
-
-
Mashup Score: 1
The preliminary findings suggest PCSK9 inhibition has anti-inflammatory effects relevant in COVID-19 and beyond.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
#PCSK9 Inhibition Shows Promise for Severe #COVID-19 in Pilot Trial The preliminary findings suggest PCSK9 inhibition has anti-inflammatory effects relevant in COVID-19 and beyond @TCTMD @ToddNeale @mmamas1973 @ShelleyZieroth @DLBHATTMD @DrMarthaGulati https://t.co/ISmi8TW9Np
-
-
Mashup Score: 0
The preliminary findings suggest PCSK9 inhibition has anti-inflammatory effects relevant in COVID-19 and beyond.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
#PCSK9 Inhibition Shows Promise for Severe #COVID-19 in Pilot Trial The preliminary findings suggest PCSK9 inhibition has anti-inflammatory effects relevant in COVID-19 and beyond @TCTMD @ToddNeale @mmamas1973 @ShelleyZieroth @DLBHATTMD @DrMarthaGulati https://t.co/ISmi8TW9Np
-
-
Mashup Score: 0Early Promise for PCSK9 Inhibition in Severe COVID-19 - 1 year(s) ago
Effects observed in inflammation and improved clinical outcomes
Source: www.medpagetoday.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#PCSK9 inhibitors could help reduce vascular inflammation to improve outcomes in severe #COVID19, a #JACC study found. Learn more about the new findings in @medpagetoday with @nicolejlou: https://t.co/60LosTkmnX #cvPrev
-
-
Mashup Score: 3PCSK9 Inhibition May Reduce Inflammation, Mortality in Patients with Severe COVID-19 - 1 year(s) ago
Patients with intense COVID-19 inflammation while infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have better survival rates with PCSK9 inhibition than with placebo treatmen
Categories: Cardiology News and Journals, Latest HeadlinesTweet-
A new #JACC study found that patients w/ intense #COVID19 inflammation while infected w/ SARS-CoV-2 have better survival rates w/ #PCSK9 than w/ placebo. Get more information on the findings in @CRT_meeting: https://t.co/9zJsvzfs9X #CardioTwitter
-
-
Mashup Score: 7
After 80 weeks of treatment, evolocumab was safe, well tolerated, and led to sustained reductions in LDL cholesterol in paediatric patients with heterozygous familial hypercholesterolaemia. When lipid goals cannot be achieved with conventional treatments, evolocumab is an effective add-on therapy in paediatric patients.
Categories: Endocrinology, Latest HeadlinesTweet-
#Paediatric patients with #heterozygous #familial #hypercholesterolaemia treated with #evolocumab for 80 weeks (#HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT https://t.co/o7iaKX24zS #PCSK9 inhibitor
-
-
Mashup Score: 4PCSK9 inhibition in children with familial hypercholesterolaemia - 1 year(s) ago
Heterozygous familial hypercholesterolaemia is the most prevalent monogenic dyslipidaemia, affecting approximately 1 in 300 people worldwide.1 If left untreated, elevated LDL cholesterol concentrations in heterozygous familial hypercholesterolaemia are associated with a more than ten-fold increased risk of premature atherosclerotic cardiovascular disease.1 For children and adolescents with…
Categories: Endocrinology, Latest HeadlinesTweet-
Robert A Hegele comments on: #PCSK9 inhibition in #children with #familial #hypercholesterolaemia https://t.co/5xmPOVTYYy #evolocumab
-
-
Mashup Score: 1Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care - 1 year(s) ago
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: EuroInterventionCategories: Cardiology News and Journals, Latest HeadlinesTweet-
"Early initiation of #PCSK9 inhibition in myocardial infarction could be EPIC for patient care". Read or 🔉listen to the audio-augmented version of the Editorial by Deepak L. Bhatt. https://t.co/igP6f96xOb https://t.co/7SyUNa1ftW
-
-
Mashup Score: 1Long-term PCSK9 inhibition plus background therapy improves LDL goal attainment in FH - 1 year(s) ago
Long-term adherence to PCSK9 inhibition was high among a high-risk cohort with familial hypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy and ezetimibe, researchers reported. This long-term prospective analysis of the Spanish Familial Hypercholesterolemia Cohort Study (SAFEHEART) was published in the European Journal of Preventive Cardiology.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Long-term adherence to #PCSK9 inhibition was high among a high-risk cohort with #FamilialHypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy + ezetimibe @ESC_Journals #cardiotwitter https://t.co/RAxa8mLhs7
-
Provocative small RCT shows #PCSK9 inhibition reduced death or need for intubation and IL-6 levels vs placebo in severe #COVID19. Patients with more intense inflammation at randomization had better survival with PCSK9 inhibition vs placebo. https://t.co/d3YSVZEnK2